Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Hypotensive action" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Heterocyclic compounds and their use as angiotensin antagonists
InactiveUS6100252AHigh yieldPotent angiotensin II receptor antagonistic activityBiocideNervous disorderDiseaseHeart disease
Compounds shown by the above formula or salt thereof show a strong angiotensin II antagonistic activity and hypotensive action and CNS activity, and are useful as therapeutic agents of circulatory diseases such as hypertensive diseases and heart diseases (e.g. hypercardia, heart failure, cardiac infarction), strokes, cerebral apoplexy, nephritis, atherosclerosis, Alzheimer's disease, senile dementia, etc.
Owner:TAKEDA PHARMACEUTICALS CO LTD
Fat-reducing products containing black tea Eurotium Cristatum and preparation thereof
InactiveCN101249112ABalance metabolismWork balanceMetabolism disorderFungi medical ingredientsBlack teaGlucose lowering
The invention relates to a beauty-slimming product containing dark green tea Euro-tium cristatum and a preparation method therof. The beauty-slimming product comprises Euro-tium cristatum which is active ingredient of Anhua dark green tea, and a plurality of extracts of medicine and food homologue, and has good real weight-reducing effect and the comprehensive function of lipid-lowering, glucose-lowering, and hypotensive action at the same time.
Owner:贺志弘
Medicinal composition for treating high blood pressure
InactiveCN1686549AInhibition levelReduce circulation levelsOrganic active ingredientsInorganic non-active ingredientsPharmaceutical SubstancesBlood vessel
A composite medicine for treating hypertension contains proportionally one or two antihypertensive medicines chosen from calcium antagon, alpha receptor blocker, beta receptor blocker, renin-angiotonin system regulator and diuretic, one Ca containing component and the farmacologically acceptable auxiliary.
Owner:苏金平
Pharmaceutical composition of atenolol/amlodipine/folacin compound and uses thereof
InactiveCN101406472AImprove antihypertensive effectTake a small doseOrganic active ingredientsCardiovascular disorderDiseaseSide effect
The invention relates to a pharmaceutical composition containing atenolol, amlodipine, or folic acid compounds and application thereof. The pharmaceutical composition contains an officinal dosage of the atenolol, an officinal dosage of the amlodipine or levamlodipine, an officinal dosage of the folic acid compounds, and a pharmaceutical acceptable carrier. The dosage of the atenolol is between 5 and 50 milligrams, the dosage of the amlodipine or the levamlodipine is between 0.5 and 5.0 milligrams, and the dosage of the folic acid type compounds is between 0.2 and 1.6 milligrams. The pharmaceutical composition has the following advantages: the pharmaceutical composition enhances the hypertension curative effect through multi-target synergistic hypotensive action, and reduces the taking dosage of the amlodipine simultaneously, that is, just about one fourth of the original dosage can achieve the same hypotensive effect and reduce the side effects and medical expenses; and more importantly, the pharmaceutical composition can effectively prevent and treat or delay various complications of high blood pressure cardiovascular and cerebrovascular diseases such as cerebrovascular disorder and the like through dual targets (Hcy and blood pressure) on the basis of reducing toxic side effects. Besides, the pharmaceutical composition ensures that patients can take medicine conveniently.
Owner:史克勇
Neurotensin as a marker and therapeutic target for sepsis
InactiveUS20080213270A1Improve survivalReduce abilityCompound screeningApoptosis detectionNeurotensin receptor 1Mast cell
Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to an infection. Neurotensin (NT) is 13-amino-acid peptide that, among its multiple effects, induces hypotension. It is shown herein that plasma concentrations of NT are increased in humans with sepsis and in mice after caecal ligation and puncture (CLP), a model of sepsis. Mast cells can degrade NT through neurotensin receptor 1- and neurolysin-dependent mechanisms, diminishing the hypotensive effects of NT, reducing intraperitoneal NT concentrations, and improving survival. These findings show that mast cells can regulate NT concentrations, and identify NT as a biomarker and therapeutic target in sepsis.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Cyclic dextrin inclusion compound of mintpress hydrochloride and its preparing method
InactiveCN1615868AAvoid residueEnsure medication safetyOrganic active ingredientsPill deliveryDrug releaseSilica gel
The cyclodextrin inclusion compound of prazosin hydrochloride consists of prazosin hydrochloride and beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin in the mass ratio of 1 / 20-1 / 5, preferably 1 / 10. The supplementary material may include hydroxypropyl methyl cellulose-400, hydroxypropyl methyl cellulose-4000, lactose, microcrystalline cellulose, compressible starch, fine silica gel powder and magnesium stearate. The preparation process of the cyclodextrin inclusion compound of prazosin hydrochloride includes the steps of: mixing beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin with water to form suspension or solution; adding prazosin hydrochloride in the amount of 1 / 20-1 / 5 via fully mixing; pressure filtering, water washing, drying to obtain the solid inclusion compound. The present invention has the effects of smooth medicine release, smooth blood pressure reduction and convenient taking.
Owner:NANJING NORMAL UNIVERSITY +1
Application of cortex mori fatty oil in preparing diuresis-inducing and blood pressure-reducing drug
InactiveCN104306449AEasy to prepareLow costBlood disorderCardiovascular disorderHypotensive actionHigh Blood Pressures
The invention discloses an application of cortex mori fatty oil in preparing a diuresis-inducing and blood pressure-reducing drug, and discusses a diuresis-inducing and blood pressure-reducing effect of the cortex mori fatty oil on SHR rat. According to the invention, the influences of the cortex mori fatty oil on urine volume of normal rats are observed by adopting a metabolic cage method of rats; and then the influences of the cortex mori fatty oil on urine volume and systolic blood pressure (SBP) of SHR rats are observed by selecting a spontaneously hypertensive rats (SHR) model and dosing for 7 days in repeated doses. The results show that compared with a control group (CMC-Na group), the cortex mori fatty oil has an obvious diuresis-inducing effect on both the normal rats and the SHR rats (P<0.01) and can significantly reduce systolic pressure of the SHR rats (P<0.01). Compared with the prior art, the invention determines that the cortex mori fatty oil components have the obvious diuresis-inducing and blood pressure-reducing effect, so that the use of the cortex mori fatty oil in preparing the diuresis-inducing and blood pressure-reducing drug is convenient, and the problem that much inconvenience is brought to patients who take the drug, due to unknown material basis of the cortex mori playing the diuresis-inducing and blood pressure-reducing effects, is overcome.
Owner:HENAN UNIV OF CHINESE MEDICINE +1
Traditional Chinese medicine composition for treating hyperpiesia
InactiveCN101716269ASpeed up micro blood flowMicro blood flow slowed downCardiovascular disorderPlant ingredientsSide effectEssential hypertension
The invention discloses a traditional Chinese medicine composition for treating hyperpiesia, prepared by extracting traditional Chinese medicines of uncaria, radix scrophulariae, hoantchy roots and rhizoma cyperi as raw materials with ethanol into pharmaceutically acceptable preparation forms, such as tablets, particle preparations, and the like. The medicament has the efficacy of clearing liver and benefiting qi, mainly treats hyperpiesia, illness irritability, insomnia, dizziness, weariness, hypodynamia, bitter taste and pulse, and the like differentiated as liver-fire qi deficiency in traditional Chinese medical science. Proved by efficacy tests, the invention has remarkable hypotensive action without toxic and side effect.
Owner:孙蓉
Mytilus crassitesta oligopeptide and use thereof
InactiveCN112457387AHigh ACE inhibitory activityNon-cytotoxicPeptide/protein ingredientsAnimals/human peptidesCytotoxicityOligopeptide
The invention provides a mytilus crassitesta oligopeptide and use thereof and belongs to the technical field of bioactive peptides. An amino acid sequence of the mytilus crassitesta oligopeptide is Leu-Ala-Ala-Ser-His or Tyr-Glu-Leu-His-Asp. The mytilus crassitesta oligopeptide provided by the invention has relatively high ACE inhibiting activity and is free of cytotoxicity, the content of an endogenous dilatation factor NO in blood vessel endothelial cells (HUVEC cells) can be increased, the content of an endogenous contraction factor ET-1 can be decreased, namely, the pressure release actionis exerted through affecting functions of the blood vessel endothelial cells. The mytilus crassitesta oligopeptide provided by the invention can be applied to preparation of health-care foods and / ormedicines with a blood pressure regulating action.
Owner:舟山市和朴海洋生物科技有限公司
Antihypertensive medicine synergist
InactiveCN103565813AImprove complianceLower doseOrganic active ingredientsCardiovascular disorderHypertension medicationsPatient compliance
Owner:刘超
Blood pressure lowering dripping pills with chryanthemum flower and pearl and its preparation process
InactiveCN1698797AFaster dissolution and absorptionImprove bioavailabilityPill deliveryCardiovascular disorderOral drug preparationClonidine Hydrochloride
Disclosed is a dripping pill for treating hypertension. The objective of the invention is to provide a medicinal composition having the advantages of high biological availability, quick-speed medicine release, quick-speed effect, higher medicinal content, easy administration, low price, and causing no pollution during production. The drop pill is prepared from powdered wild chrysanthemum flower, pearl powder, clonidine hydrochloride, hydrochlorothiazidum, globularicitrin as raw material, and medicinal carrying agent as the base material.
Owner:广西宝瑞坦广明制药有限公司
Application of miRNA (micro-ribonucleic acid) miR-21 to glaucoma treatment
The invention provides an application of miRNA (micro-ribonucleic acid) miR-21 to glaucoma treatment and specifically provides an application of an active component. The active component is selected from the following groups: (a) miRNA from miRNA-21; (b) precursor miRNA; (c) polynucleotide; (d) an expression vector; (e) an agonist of miRNA in (a); the active component is used for preparing pharmaceutical composition which is used for preventing and / or treating glaucoma and / or reducing IOP (intraocular pressure). About 20% of pressure reduction can be realized by miRNA miR-21, and the pressurereduction effect keeps for 48 h which is longer than that of most drugs clinically.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment
The invention relates to a substained release form of hydralazine for use in cancer therapy. The substained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.
Owner:PSICOFARMA S A DE
Hypotensive drug pillow
InactiveCN104873047AEasy to useNo side effectsPillowsAnthropod material medical ingredientsChrysanthemum FlowerPharmaceutical drug
The invention belongs to a drug pillow, and particularly relates to a hypotensive drug pillow. The hypotensive drug pillow comprises a pillow core and a pillow sleeve; the pillow core fills with traditional Chinese medicine prepared by crushing and mixing; the traditional Chinese medicine contains the following raw materials in part by weight: 2-5 parts of radix puerariae, 2-5 parts of wild chrysanthemum flower, 2-5 parts of buckwheat hull, 1-3 parts of mint, 1-3 parts of semen cassiae, 1-3 parts of prunella spike, 1-3 parts of gastrodia elata, and 1-3 parts of silkworm excrement. The hypotensive drug pillow is convenient to use, safe and reliable, free from toxic and side effects, and obvious in hypotensive effect.
Owner:ANHUI XIAZHEN GRP
Pharmaceutical Composition For The Sustained Release Of Hydralazine And Use Thereof As A Support For Cancer Treatment
The invention relates to a sustained release form of hydralazine for use in cancer therapy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.
Owner:PSICOFARMA S A DE
Combinations of SGLT 2 inhibitors and antihypertensive drugs
InactiveUS20150320721A1Good treatment effectLower blood pressureBiocideAntimycoticsCvd riskDiabetic nephropathy
Medicaments that depend on a combination of SGLT 2 inhibitors and antihypertensive drugs and which are useful in the treatment of diseases involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events, as well as methods of treating the diseases are provided. Since the present invention exhibits a superior hypotensive action that cannot be attained by any single antihypertensive drugs, the conventional problems associated with the use of two or more antihypertensive drugs in order to lower the blood pressure to the desired level can be solved. In addition, the present invention shows a marked therapeutic efficacy in diabetes mellitus, a disease associated with diabetes mellitus, or complications of diabetes mellitus, in particular, diabetic nephropathy. As a further advantage, the present invention is also useful for the treatment of diseases involving lowered renal function.
Owner:TAISHO PHARMACEUTICAL CO LTD
A plant extract composition with antihypertensive effect, its preparation method and application
ActiveCN108295131BSuitable for long-term useSimple processCardiovascular disorderPlant ingredientsEfficacyCurative effect
The invention relates to a plant extract composition with antihypertensive effect, its preparation method and application. The plant extract composition is composed of the extracts of the root of the plant, the extract of the core of the hawthorn and the extract of the lacquer in the ratio of 7-12:3-5:1-4, and the composition can reduce the diastolic pressure and / or contraction of the arteries Pressure, for the preparation of antihypertensive drugs. The raw materials used in the composition are cheap and easy to obtain, the cost is low, the preparation method is simple, the synergistic effect is exerted among the compositions, the curative effect is definite, safe and reliable, the blood pressure lowering effect is good, and the application and popularization are convenient.
Owner:吉百瑞医药生物科技(深圳)有限公司
PEPTOID-PEPTIDE HYBRID, NMEG-aCGRP, AND ITS USE IN CARDIOVASCULAR DISEASES
NMEG-αCGRP, a biologically active molecule, and systems and methods of use therefore, subcutaneous administration of NMEG-αCGRP, a non-toxic peptoid-peptide hybrid that possesses hypotensive action, employed as a therapeutic agent to treat and prevent various cardiovascular diseases, including, heart failure (pressure. as well as volume, overload), myocardial infarction, cardiomyopathy, and hypertension.
Owner:BOARD OF TRUSTEES OF THE UNVIERSITY OF ARKANSAS +1
A method for preparing medicine for treating hypertension with Radix Paeoniae Alba and Dendrobium officinale
ActiveCN108635511BBlood pressure drops fasterImprove long-term antihypertensive effectNatural extract food ingredientsFood ingredient functionsOral treatmentEfficacy
The invention relates to medicine preparation technology, and aims to provide a method for preparing medicine for treating hypertension with Radix Paeoniae Alba and Dendrobium officinale. It includes: grinding white peony root into powder, extracting with alcohol, extracting the residue after alcohol extraction with water, and combining the concentrated extract; grinding Dendrobium candidum into powder, adding it to the combined extract, and adding auxiliary materials to prepare it for treatment Medicines for high blood pressure. In the present invention, the extract of Paeoniae Alba and Dendrobium officinale powder has outstanding curative effect on treating hypertension, and its antihypertensive effect can exceed that of western medicine irbesartan. Compared with conventional water extraction, the double extraction method of white peony alcohol reduces the loss of components and improves the effectiveness, promotes the complete utilization of white peony oral treatment by the human body, and improves the curative effect. It has a selective adjustment effect on hypertensive patients and has no effect on normal blood pressure: it has the effect of lowering blood pressure on hypertensive patients, but has no effect on normal blood pressure, and will not reduce high blood pressure below normal. This is also an advantage over most western antihypertensive drugs.
Owner:HANGZHOU DANHE PHARM CO LTD
Flounder surimi having antioxidant and antihypertensive effects and method of preparing the same
ActiveUS20200179481A1Lower blood pressureTreating and preventing hypertensionHydrolysed protein ingredientsTetrapeptide ingredientsAntioxidative stressHydrolysate
Disclosed is a pharmaceutical composition or food composition for the treatment or prevention of hypertension, containing a peptide isolated from a fraction of a flounder surimi hydrolysate as an active ingredient and is based on the finding that the flounder surimi has an effect of reducing blood pressure, and the hydrolysate of the flounder surimi, the fraction of the hydrolysate of the flounder surimi and peptides isolated from the fraction of the hydrolysate of the flounder surimi have an inhibition activity against an angiotensin I converting enzyme (ACE). Thus, peptides isolated from the fraction of the hydrolysate of the flounder surimi can be used for pharmaceutical compositions or food compositions for treating or preventing hypertension. Also, the present invention is based on the finding that the hydrolysate of the flounder surimi and peptides isolated therefrom have radical scavenging effect and a protective effect against oxidative stress and are thus capable of inhibiting ROS production, lipid peroxidation and apoptosis. Accordingly, peptides isolated from fractions of the hydrolysate of the flounder surimi can be used for food compositions for antioxidation.
Owner:IND ACADEMIC COOPERATION FOUND JEJU NAT UNIVERSTIY
Oligopeptide with blood pressure reducing function, and preparation method and application thereof
ActiveCN111254174APromote the effect of enzymatic hydrolysisImprove enzymatic hydrolysis efficiencyProtein composition from fishHydrolysed protein ingredientsBio engineeringOligopeptide
The invention discloses an oligopeptide with a blood pressure reducing function, and a preparation method and application thereof, and belongs to the field of biological engineering. According to thetechnical scheme, the preparation method of the oligopeptide with the blood pressure reducing effect comprises the following steps: A, fermenting a soybean meal raw material to obtain fermented soybean meal, wherein the fermentation strain is butyric acid bacteria; B, carrying out secondary fermentation treatment on the fermented soybean meal in the step A with a cuttlefish crushed material to obtain a mixed base material, wherein the fermentation strain is butyric acid bacteria; C, carrying out enzymolysis on the mixed base material in the step B by adopting ultrasonic assisted enzymolysis toobtain an enzymolysis liquid; and D, filtering the enzymolysis liquid obtained in the step C, and performing purification and drying to obtain the oligopeptide with the blood pressure reducing effect. The oligopeptide provided by the invention has the beneficial effects that the selected oligopeptide provided by the invention contains characteristic amino acid for inhibiting the angiotensin I-converting enzyme (ACE), and distribution is uniform. The content of the amino acid is high, so that activity of the provided oligopeptide is high, the inhibition effect on the ACE is good, and the bloodpressure reducing effect is increased.
Owner:CHINA YUNHONG HLDG CO LTD +1
Functional food with antihypertensive effect and preparation device thereof
PendingCN113826845AEasy to synthesizeIncrease blood flowFood shapingNatural extract food ingredientsCranial nervesSpleen
The invention provides a functional food with an antihypertensive effect and a preparation device thereof, and belongs to the technical field of health care products. The invention provides the functional food with an antihypertensive effect. The functional food is prepared from the following components in percentage by mass of 30-45% of carrot powder, 15-30% of blueberry powder, 3-6% of ginseng, 4-8% of hawthorn, 1-3% of cordyceps militaris, 4-8% of wax gourd and 3-5% of oyster extract. The carrot powder is used as a main raw material of the functional food for reducing blood pressure, can promote synthesis of epinephrine, increase coronary artery blood flow volume, has the effects of reducing blood pressure and diminishing inflammation, and can prevent cranial nerve aging, soften blood vessels and enhance human immunity by being matched with the blueberry powder; and meanwhile, ginseng, hawthorn, cordyceps militaris, wax gourd and oyster extract are matched, so that the antihypertensive effect can be enhanced, and the health-care functions of strengthening the spleen and stomach and enhancing the physical quality are also achieved. The invention further provides the preparation device of the functional food with the antihypertensive effect.
Owner:珠海无糖无恙健康科技有限公司
Plant extract with angiotensin converting enzyme inhibitor function and use thereof
InactiveCN101361826ARich sourcesAbundant resourcesCardiovascular disorderPlant ingredientsAngiotensin-converting enzymeFiltration
The invention relates to a plant extract which has the function of an angiotensin-converting enzyme inhibitor and the application thereof, belonging to the technical field of chemical component extraction of plants. The preparation process is as follows: rose is dried and the dried rosebuds are ground into powder; ethanol with concentration of 50 percent to 95 percent is used for extraction for 3 times; filtrations are carried out for 3 times and the extract is combined; the extract is decompressed and condensed into extractum; then ethanol with concentration of 50 percent is used for extraction for three times and the extract is combined, decompressed, cooled and dried. After pharmacology and pharmacodynamics tests, the analysis on the activity of lowering blood pressure of the rosebud ethanolic extract is carried out; the extract is found to be capable of effectively inhibiting the activity of angiotensin-converting enzyme and obviously lowering the blood pressure of hypertensive rats of two-kidney and one-clip type and being capable of being used for preparing medicines or health care products for curing or preventing hypertension. The preparation method of the extract is simple and practical and the plant extract prepared by the invention has obvious effect of lowering blood pressure and good application safety.
Owner:NANJING AGRICULTURAL UNIVERSITY
Application of Dendrobium officinale leaves, sealwort and radish seeds in the preparation of drugs for treating hypertension
ActiveCN109700939BGood blood pressure effectStable antihypertensive effectPharmaceutical delivery mechanismCardiovascular disorderBiotechnologyHypertension medications
Owner:HANGZHOU DANHE PHARM CO LTD
Combinations of SGLT 2 inhibitors and antihypertensive drugs
InactiveUS9320727B2Good treatment effectLower blood pressureAntimycoticsMetabolism disorderCvd riskDiabetic nephropathy
Medicaments that depend on a combination of SGLT 2 inhibitors and antihypertensive drugs and which are useful in the treatment of diseases involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events, as well as methods of treating the diseases are provided. Since the present invention exhibits a superior hypotensive action that cannot be attained by any single antihypertensive drugs, the conventional problems associated with the use of two or more antihypertensive drugs in order to lower the blood pressure to the desired level can be solved. In addition, the present invention shows a marked therapeutic efficacy in diabetes mellitus, a disease associated with diabetes mellitus, or complications of diabetes mellitus, in particular, diabetic nephropathy. As a further advantage, the present invention is also useful for the treatment of diseases involving lowered renal function.
Owner:TAISHO PHARMACEUTICAL CO LTD
A natural isochromanone compound for lowering blood pressure
ActiveCN110272407BGood antihypertensive effectRich sourcesOrganic active ingredientsOrganic chemistrySpontaneously hypertensive ratEssential hypertension
The invention relates to a natural isochromanone compound. The compound has an excellent antihypertensive effect on both the blood pressure of spontaneously hypertensive rats (SHR) and the blood pressure of C57BL / 6 mice mediated by angiotensin II, and a unique effect of the compound on prevention and treatment of the hypertension is shown. The compound is derived from uncaria tomentosa, has rich sources, can be obtained through simple and convenient extraction and separation processes, and can be prepared on a large scale.
Owner:河北省农林科学院经济作物研究所
Blood pressure lowering composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata
ActiveUS10702564B2Good ACE inhibitory activityLower blood pressureBiocideSnake antigen ingredientsBiotechnologyBULK ACTIVE INGREDIENT
The present invention relates to a blood pressure lowering composition which contains as an active ingredient exopolysaccharide produced by means of Ceriporia lacerata, a Ceriporia lacerata mycelium culture medium comprising same, or dry powder or an extract of same. The composition can be used as an antihypertensive for preventing or treating hypertension or cerebral apoplexy or as a functional health food having antihypertensive effect.
Owner:FUGENBIO
A kind of oligopeptide with antihypertensive effect and its preparation method and application
ActiveCN111254174BGood blood pressure effectStrong inhibitory activityProtein composition from fishHydrolysed protein ingredientsBio engineeringOligopeptide
The invention discloses an oligopeptide with a blood pressure reducing function, and a preparation method and application thereof, and belongs to the field of biological engineering. According to thetechnical scheme, the preparation method of the oligopeptide with the blood pressure reducing effect comprises the following steps: A, fermenting a soybean meal raw material to obtain fermented soybean meal, wherein the fermentation strain is butyric acid bacteria; B, carrying out secondary fermentation treatment on the fermented soybean meal in the step A with a cuttlefish crushed material to obtain a mixed base material, wherein the fermentation strain is butyric acid bacteria; C, carrying out enzymolysis on the mixed base material in the step B by adopting ultrasonic assisted enzymolysis toobtain an enzymolysis liquid; and D, filtering the enzymolysis liquid obtained in the step C, and performing purification and drying to obtain the oligopeptide with the blood pressure reducing effect. The oligopeptide provided by the invention has the beneficial effects that the selected oligopeptide provided by the invention contains characteristic amino acid for inhibiting the angiotensin I-converting enzyme (ACE), and distribution is uniform. The content of the amino acid is high, so that activity of the provided oligopeptide is high, the inhibition effect on the ACE is good, and the bloodpressure reducing effect is increased.
Owner:CHINA YUNHONG HLDG CO LTD +1
Compound medicinal composition for reducing blood pressure, and compound tablet for reducing blood pressure
ActiveCN102327263BGood antihypertensive effectProlong biological half-lifeOrganic active ingredientsPill deliveryLevamlodipinePharmaceutical drug
The invention discloses a compound medicinal composition for reducing blood pressure and a compound tablet for reducing blood pressure. The compound medicinal composition for reducing blood pressure comprises levamlodipine or pharmaceutically acceptable salt thereof and indapamide, wherein the weight ratio of indapamide to levamlodipine is 1:(1.5-12). The novel compound preparation for reducing blood pressure improves the effect of reducing blood pressure by using synergism among medicines, has a stable effect of reducing blood pressure and excellent cost performance, reduces a side effect, and can be widely popularized and applied to crowds. The compound tablet for reducing blood pressure has high stability and can effectively prolong a validity period.
Owner:KANGYA OF NINGXIA PHARMA +1
External traditional Chinese medicine compound plaster with antihypertensive effect
InactiveCN113577154AEasy to useImprove the effect of treating high blood pressureSheet deliveryCardiovascular disorderCyathula officinalisAntihypertensive medication
The invention belongs to the technical field of traditional Chinese medicine emplastrum, and particularly relates to an external traditional Chinese medicine compound emplastrum with an antihypertensive effect, and the external traditional Chinese medicine compound emplastrum with the antihypertensive effect is prepared from the following specific raw materials in parts by weight: 0.5-1.5 parts of uncaria, 0.5-1.5 parts of herba lycopi, 1-3 parts of radix puerariae and 0.5-1.5 parts of radix cyathulae. The traditional Chinese medicine compound plaster is directly and externally applied to the skin of a human body without being directly orally taken, so that the plaster is relatively convenient to use, the body is not slightly hurt in the process of reducing blood pressure by orally taking a blood pressure reducing medicine, and the effect of treating hypertension is greatly improved.
Owner:杨云霜
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com